베타
임상 레이더 AI
임상시험 NCT05218447 (DOOR SCI)은(는) 척수 손상에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰

Dosing of Overground Robotic Gait Training with Functional Outcomes and Neuroplasticity After Spinal Cord Injury (DOOR SCI)

모집중
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '시험 설명하기'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT05218447 (DOOR SCI)은(는) 척수 손상에 대해 알아보는 중재연구입니다. 현재 상태는 모집중이며, 연구는 2022년 5월 20일에 시작되어 144명의 참여자를 모집하고 있습니다. Baylor Research Institute이(가) 진행하며, 2025년 9월 14일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2025년 2월 6일에 갱신되었습니다.
간단한 개요
The DOOR SCI project examines dosing effects of robotic gait training (RGT) and transcranial magnetic stimulation (TMS) initiated during inpatient rehabilitation and continued through early outpatient rehabilitation
상세한 설명
Emerging evidence indicates that robotic exoskeleton use results in positive outcomes for those with chronic SCI, yet limited evidence exists for the acute setting. The potential benefit of RGT initiated during inpatient rehabilitation when recovery is greatest is unknown yet appears promising due to established principles of neuroplasticity and the fact that RGT incorporates the critical components of gait training. As a result of the lack of evidence, no clinical practice guidelines exist that delineate which gait retraining approach or dose during early phases of recovery results in the best outcomes for people with motor incomplete SCI. The DOOR SCI project examines dosing effects on 5 occasions over 9 months: (1) inpatient rehabilitation admission and (2) discharge, (3) after completing 24 RGT sessions, (4) 1-month post RGT, and (5) 9-months post SCI). To test the overarching goal, investigators propose three specific aims:

Aim 1: Using a randomized controlled trial, prospectively examine whether the dosing frequency [24 sessions delivered as high, moderate, or low frequency, defined by number days/week (4, 3, or 2 days/week over 6, 8, 12 weeks)] of RGT therapy provided during the acute/subacute recovery phase after motor incomplete SCI impacts outcomes compared to usual care only.

Aim 2: Investigate the difference over 9 months of the neuroplastic effect of RGT dosing as measured by single pulse TMS.

Aim 3: Evaluate the safety, tolerability, and feasibility of delivering different dosing frequencies of RGT from inpatient to outpatient rehabilitation settings.

공식 제목

Dosing of Overground Robotic Gait Training with Functional Outcomes and Neuroplasticity After Spinal Cord Injury

질환/상태
척수 손상
출판물
이 임상 시험에 대해 발표된 과학 논문 및 연구 자료.
기타 연구 식별자
  • DOOR SCI
  • BSWRI IRB 021-205
NCT 번호
실제 연구 시작일
2022-05-20
최신 업데이트 게시
2025-02-06
예상 연구 완료일
2025-09-14
계획된 등록 인원
144
연구종류
중재연구
단계/상
해당 없음
상태
모집중
키워드
Exoskeleton
Wearable assistive technology
Transcranial magnetic stimulation
Robotic gait training
주요 목적
치료
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
삼중맹검
시험군 / 개입
참가자 그룹/시험군개입/치료
실험적Low Frequency
Subjects will receive 2 sessions of robotic gait training (RGT) per week for 12 weeks
Robotic Gait Training
Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting. Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity.
실험적Moderate Frequency
Subjects will receive 3 sessions of robotic gait training (RGT) per week for 8 weeks
Robotic Gait Training
Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting. Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity.
실험적High Frequency
Subjects will receive 4 sessions of robotic gait training (RGT) per week for 6 weeks
Robotic Gait Training
Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting. Subjects will wear an exoskeleton device and receive robotic gait training (RGT) with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will complete 24 robotic gait training sessions over different durations during outpatient rehabilitation. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity.
활성 대조군Control Group
Subjects will receive usual care gait training without robotic gait training
Usual Care (UC) Gait Training
Subjects will be randomized to one of 4 gait training group. The duration of treatment will span across their inpatient rehabilitation length of stay after providing informed consent to their 9 months post-SCI visit in the outpatient rehabilitation setting. Subjects will complete gait training with a physical therapist during a 45-minutes inpatient rehabilitation session. Subjects will also complete a transcranial magnetic stimulation (TMS) assessment and questionnaires about walking and function. Subjects will be asked to wear an activity monitor to measure their activity.
주요결과변수
결과변수측정값 설명시간 범위
Change in Walking Index for Spinal Cord Injury - II (WISCI-II) from baseline
The WISCI-II defines the physical limitation for gait secondary to impairment at the person level and indicates the ability of a person to walk after SCI. The WISC-II rank orders the ability a person to walk on a scale of 0-20 with 0 representing no ability to stand or participate in assisted walking and 20 representing an ability to walk 10 meters with no devices, no braces, and no physical assistance.
Change in baseline, within 5 days of discharge, within 5 days post-intervention (RGT Groups) or 1-month post-discharge (UC group), 1-month post-intervention or 2-months post-discharge (UC group) (5) 9-months post-SCI onset
이차결과변수
결과변수측정값 설명시간 범위
Change in 10-Meter Walk Test (10MWT)
The 10MWT assesses gait speed (m/s) over a short duration.
Change in baseline, within 5 days of discharge, within 5 days post-intervention (RGT Groups) or 1-month post-discharge (UC group), 1-month post-intervention or 2-months post-discharge (UC group) (5) 9-months post-SCI onset
Change in Spinal Cord Independence Measure (SCIM)
The SCIM assesses the ability of a person with spinal cord injury (SCI) to preform specified tasks independently, with assistance, or with assistive devices. SCIM is composed of 19 items with total SCIM scores ranging from 0 (required assistance) to 100 (independence). A higher score means greater independence.
Change in baseline, within 5 days of discharge, within 5 days post-intervention (RGT Groups) or 1-month post-discharge (UC group), 1-month post-intervention or 2-months post-discharge (UC group) (5) 9-months post-SCI onset
Change in Numerical Pain Rating Scale (NPRS)
Pain is a significant problem in many individuals with SCI. A 0-10 Point Numerical Pain Rating Scale (NRS) is recommended as the outcome measure for pain intensity after SCI during acute and subacute phases. Pain severity can be categorized into 3 distinct groups as relates to pain interference: 1-3 (mild), 4-7 (moderate), 8-10 (severe). A higher score means greater pain severity.
Change in baseline, within 5 days of discharge, within 5 days post-intervention (RGT Groups) or 1-month post-discharge (UC group), 1-month post-intervention or 2-months post-discharge (UC group) (5) 9-months post-SCI onset
Change in Fatigue Severity Scale (FSS)
The Fatigue Severity Scale (FSS) is used to measure fatigue in neurologic disorders and measures the effects of fatigue on function. It is measure on the following scale: 1. \- Strongly Disagree 2. \- Disagree 3. \- Slightly Disagree 4. \- Neutral 5. \- Slightly Agree 6. \- Agree 7. \- Strongly Agree A higher score means greater fatigue.
Change in baseline, within 5 days of discharge, within 5 days post-intervention (RGT Groups) or 1-month post-discharge (UC group), 1-month post-intervention or 2-months post-discharge (UC group) (5) 9-months post-SCI onset
Change in Penn Spasm Frequency Scale (PSFS)
The PSFS is a self-report measure to assess a patient's perception of spasticity frequency and severity following a SCI. With excellent internal consistency (ICC = 0.90), the current version was modified from the original to include both frequency and severity. A higher score means greater magnitude in spasms.
Change in baseline, within 5 days of discharge, within 5 days post-intervention (RGT Groups) or 1-month post-discharge (UC group), 1-month post-intervention or 2-months post-discharge (UC group) (5) 9-months post-SCI onset
Change in Patient Health Questionnaire - 9 (PHQ-9)
The PHQ-9 is a self-report measure to assess the presence of depressive symptoms. Each items is scored on the following scale: 0 - not at all 1. \- several days 2. \- more than half the days 3. \- nearly daily Total scores are calculated by adding all the score and provides a possible depression severity score: none (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27). A higher score means greater severity in depressive symptoms.
Change in baseline, within 5 days of discharge, within 5 days post-intervention (RGT Groups) or 1-month post-discharge (UC group), 1-month post-intervention or 2-months post-discharge (UC group) (5) 9-months post-SCI onset
Change in Life Satisfaction Questionnaire (LISAT)
The LISAT is a nine-item quality of life questionnaire suitable for SCI populations containing a single item assessing overall life satisfaction, along with eight additional domain-specific items. Items are answered on a 6-point likert scale that ranges from 1 (very dissatisfied), to 6 (very satisfied). The total Life Satisfaction score is computed as the mean of the item scores and the results are divided into dissatisfied (1-4) and satisfied (5-6). A higher score score means greater life satisfaction.
Change in baseline, within 5 days of discharge, within 5 days post-intervention (RGT Groups) or 1-month post-discharge (UC group), 1-month post-intervention or 2-months post-discharge (UC group) (5) 9-months post-SCI onset
Change in Physical Activity by GT9x Actigraph accelerometer
Active energy expenditure will be measured in counts per day using a GT9x Actigraph accelerometer. Patient will be instructed to wear the watch on an unaffected wrist for one week. Higher counts represent greater physical activity.
Change in baseline, within 5 days of discharge, within 5 days post-intervention (RGT Groups) or 1-month post-discharge (UC group), 1-month post-intervention or 2-months post-discharge (UC group) (5) 9-months post-SCI onset
Change in Neurophysiologic biomarkers by single pulse transcranial magnetic stimulation (TMS)
Motor evoked potential (MEP) amplitudes will be measured and indexed from lower extremity muscle by single pulse transcranial magnetic stimulation (TMS).
Change in baseline, within 5 days of discharge, within 5 days post-intervention (RGT Groups) or 1-month post-discharge (UC group), 1-month post-intervention or 2-months post-discharge (UC group) (5) 9-months post-SCI onset
적격성 기준

연령대
어린이, 성인, 노인
최소 연령
16 Years
참여 가능한 성별
전체
  • All types of motor incomplete SCI (traumatic and non-traumatic)
  • Acute/Subacute phase of recovery
  • Medically stable as deemed by physician
  • Undergoing medical care and rehabilitation at Baylor Scott & White Institute for Rehabilitation
  • Both genders and all races and ethnicities
  • Meet the Ekso robotic exoskeleton frame limitations
  • Continence of or a program for bladder and bowel management

  • Concurrent moderate to severe traumatic brain injury (TBI)
  • Degenerative diagnoses
  • Pre-morbid developmental disability, significant psychological diagnosis, or other cognitive impairment
  • Pregnancy
Baylor Research Institute logoBaylor Research Institute
  • United States Department of Defense logoUnited States Department of Defense
  • Texas Woman's University logoTexas Woman's University
연구 책임자
Chad Swank, 책임연구자, Research Investigator, Baylor Research Institute
연구 대표 연락처
연락처: Faith Meza, MPH, 469-531-1577, [email protected]
연락처: Christa Ochoa, MPH, [email protected]
1 1개국에 임상시험 장소

Texas

Baylor Scott & White Institute for Rehabilitation, Dallas, Texas, 75246, United States
Baylor Scott & White Institute for Rehabilitation, 연락처
모집중